vs
Apellis Pharmaceuticals, Inc.（APLS）与Dave Inc.（DAVE）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Dave Inc.的1.2倍（$199.9M vs $163.7M），Dave Inc.净利率更高（40.3% vs -29.5%，领先69.8%），Dave Inc.同比增速更快（62.4% vs -5.9%），Dave Inc.自由现金流更多（$289.7M vs $-14.3M），过去两年Dave Inc.的营收复合增速更高（49.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Dave & Buster's是总部位于美国达拉斯的餐饮娱乐连锁品牌，旗下门店均配套全服务餐厅、酒吧，以及名为“百万美元中途岛”的电子游戏厅。截至2024年2月，品牌在美国拥有158家门店，波多黎各和加拿大各设有2家门店。
APLS vs DAVE — 直观对比
营收规模更大
APLS
是对方的1.2倍
$163.7M
营收增速更快
DAVE
高出68.3%
-5.9%
净利率更高
DAVE
高出69.8%
-29.5%
自由现金流更多
DAVE
多$304.0M
$-14.3M
两年增速更快
DAVE
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $163.7M |
| 净利润 | $-59.0M | $65.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 39.2% |
| 净利率 | -29.5% | 40.3% |
| 营收同比 | -5.9% | 62.4% |
| 净利润同比 | -62.2% | 292.4% |
| 每股收益（稀释后） | $-0.40 | $4.60 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSDAVE
| Q4 25 | $199.9M | $163.7M | ||
| Q3 25 | $458.6M | $150.7M | ||
| Q2 25 | $178.5M | $131.8M | ||
| Q1 25 | $166.8M | $108.0M | ||
| Q4 24 | $212.5M | $100.8M | ||
| Q3 24 | $196.8M | $92.5M | ||
| Q2 24 | $199.7M | $80.1M | ||
| Q1 24 | $172.3M | $73.6M |
净利润APLSDAVE
| Q4 25 | $-59.0M | $65.9M | ||
| Q3 25 | $215.7M | $92.1M | ||
| Q2 25 | $-42.2M | $9.0M | ||
| Q1 25 | $-92.2M | $28.8M | ||
| Q4 24 | $-36.4M | $16.8M | ||
| Q3 24 | $-57.4M | $466.0K | ||
| Q2 24 | $-37.7M | $6.4M | ||
| Q1 24 | $-66.4M | $34.2M |
营业利润率APLSDAVE
| Q4 25 | -25.6% | 39.2% | ||
| Q3 25 | 48.7% | 38.8% | ||
| Q2 25 | -18.6% | 8.7% | ||
| Q1 25 | -50.0% | 31.4% | ||
| Q4 24 | -12.3% | 17.3% | ||
| Q3 24 | -24.0% | 0.9% | ||
| Q2 24 | -14.7% | 5.7% | ||
| Q1 24 | -36.0% | 50.9% |
净利率APLSDAVE
| Q4 25 | -29.5% | 40.3% | ||
| Q3 25 | 47.0% | 61.1% | ||
| Q2 25 | -23.6% | 6.9% | ||
| Q1 25 | -55.3% | 26.7% | ||
| Q4 24 | -17.1% | 16.7% | ||
| Q3 24 | -29.2% | 0.5% | ||
| Q2 24 | -18.9% | 7.9% | ||
| Q1 24 | -38.5% | 46.5% |
每股收益（稀释后）APLSDAVE
| Q4 25 | $-0.40 | $4.60 | ||
| Q3 25 | $1.67 | $6.34 | ||
| Q2 25 | $-0.33 | $0.62 | ||
| Q1 25 | $-0.74 | $1.97 | ||
| Q4 24 | $-0.30 | $1.09 | ||
| Q3 24 | $-0.46 | $0.03 | ||
| Q2 24 | $-0.30 | $0.47 | ||
| Q1 24 | $-0.54 | $2.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $80.5M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | $370.1M | $352.7M |
| 总资产 | $1.1B | $487.4M |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资APLSDAVE
| Q4 25 | $466.2M | $80.5M | ||
| Q3 25 | $479.2M | $49.9M | ||
| Q2 25 | $370.0M | $61.8M | ||
| Q1 25 | $358.4M | $47.1M | ||
| Q4 24 | $411.3M | $49.8M | ||
| Q3 24 | $396.9M | $35.2M | ||
| Q2 24 | $360.1M | $48.7M | ||
| Q1 24 | $325.9M | $56.6M |
总债务APLSDAVE
| Q4 25 | — | $0 | ||
| Q3 25 | — | $75.0M | ||
| Q2 25 | — | $75.0M | ||
| Q1 25 | — | $75.0M | ||
| Q4 24 | — | $75.0M | ||
| Q3 24 | — | $75.0M | ||
| Q2 24 | — | $75.0M | ||
| Q1 24 | $93.1M | $75.0M |
股东权益APLSDAVE
| Q4 25 | $370.1M | $352.7M | ||
| Q3 25 | $401.2M | $291.3M | ||
| Q2 25 | $156.3M | $217.1M | ||
| Q1 25 | $164.2M | $199.5M | ||
| Q4 24 | $228.5M | $183.1M | ||
| Q3 24 | $237.1M | $155.8M | ||
| Q2 24 | $264.3M | $141.8M | ||
| Q1 24 | $266.7M | $127.3M |
总资产APLSDAVE
| Q4 25 | $1.1B | $487.4M | ||
| Q3 25 | $1.1B | $433.3M | ||
| Q2 25 | $821.4M | $363.6M | ||
| Q1 25 | $807.3M | $315.7M | ||
| Q4 24 | $885.1M | $299.3M | ||
| Q3 24 | $901.9M | $272.2M | ||
| Q2 24 | $904.5M | $247.2M | ||
| Q1 24 | $831.9M | $235.6M |
负债/权益比APLSDAVE
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.38× | ||
| Q4 24 | — | 0.41× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | 0.35× | 0.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $290.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $289.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 177.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.2% |
| 现金转化率经营现金流/净利润 | — | 4.40× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $486.2M |
8季度趋势，按日历期对齐
经营现金流APLSDAVE
| Q4 25 | $-14.2M | $290.0M | ||
| Q3 25 | $108.5M | $83.2M | ||
| Q2 25 | $4.4M | $68.2M | ||
| Q1 25 | $-53.4M | $45.2M | ||
| Q4 24 | $19.4M | $125.1M | ||
| Q3 24 | $34.1M | $37.0M | ||
| Q2 24 | $-8.3M | $28.0M | ||
| Q1 24 | $-133.0M | $18.3M |
自由现金流APLSDAVE
| Q4 25 | $-14.3M | $289.7M | ||
| Q3 25 | $108.3M | $83.2M | ||
| Q2 25 | $4.4M | $68.1M | ||
| Q1 25 | $-53.4M | $45.2M | ||
| Q4 24 | $19.3M | $124.9M | ||
| Q3 24 | — | $37.0M | ||
| Q2 24 | $-8.4M | $27.9M | ||
| Q1 24 | $-133.3M | $18.3M |
自由现金流率APLSDAVE
| Q4 25 | -7.1% | 177.0% | ||
| Q3 25 | 23.6% | 55.2% | ||
| Q2 25 | 2.5% | 51.7% | ||
| Q1 25 | -32.0% | 41.9% | ||
| Q4 24 | 9.1% | 123.8% | ||
| Q3 24 | — | 40.0% | ||
| Q2 24 | -4.2% | 34.8% | ||
| Q1 24 | -77.3% | 24.9% |
资本支出强度APLSDAVE
| Q4 25 | 0.1% | 0.2% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | 0.2% | 0.0% |
现金转化率APLSDAVE
| Q4 25 | — | 4.40× | ||
| Q3 25 | 0.50× | 0.90× | ||
| Q2 25 | — | 7.55× | ||
| Q1 25 | — | 1.57× | ||
| Q4 24 | — | 7.45× | ||
| Q3 24 | — | 79.47× | ||
| Q2 24 | — | 4.41× | ||
| Q1 24 | — | 0.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
DAVE
| Service Based Revenue | $153.2M | 94% |
| Interchange Revenue Net | $6.4M | 4% |
| Transaction Based Revenue Other Net | $4.1M | 3% |
